ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 212 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q2 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,417,427 | -27.0% | 211,241 | -3.9% | 0.01% | +20.0% |
| Q1 2023 | $1,940,728 | +60.5% | 219,788 | +38.9% | 0.01% | -37.5% |
| Q4 2022 | $1,209,144 | +7.1% | 158,265 | -0.2% | 0.01% | -42.9% |
| Q3 2022 | $1,129,000 | +72.1% | 158,584 | +95.4% | 0.01% | +100.0% |
| Q2 2022 | $656,000 | -39.4% | 81,157 | +4.1% | 0.01% | -58.8% |
| Q1 2022 | $1,082,000 | -26.4% | 77,934 | +48.7% | 0.02% | -22.7% |
| Q4 2021 | $1,470,000 | -40.0% | 52,400 | -27.3% | 0.02% | -59.3% |
| Q3 2021 | $2,450,000 | -11.0% | 72,084 | +7.0% | 0.05% | -10.0% |
| Q2 2021 | $2,752,000 | +20.3% | 67,353 | +18.5% | 0.06% | +11.1% |
| Q1 2021 | $2,288,000 | -13.6% | 56,826 | +26.9% | 0.05% | -36.5% |
| Q4 2020 | $2,647,000 | +21.1% | 44,772 | -0.4% | 0.08% | -5.6% |
| Q3 2020 | $2,185,000 | +845.9% | 44,939 | +839.6% | 0.09% | +592.3% |
| Q2 2020 | $231,000 | – | 4,783 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 3,030,434 | $23,152,516 | 15.55% |
| BERYLSON CAPITAL PARTNERS, LLC | 289,726 | $2,213,507 | 6.45% |
| Matrix Capital Management Company, LP | 11,572,590 | $88,414,588 | 1.69% |
| Pier Capital, LLC | 1,012,401 | $7,734,744 | 1.27% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $229,151,929 | 1.15% |
| Eagle Health Investments LP | 607,860 | $4,644,050 | 1.07% |
| Triatomic Management LP | 130,805 | $999,350 | 0.84% |
| Aristotle Atlantic Partners, LLC | 1,880,567 | $14,367,532 | 0.80% |
| Senator Investment Group LP | 1,000,000 | $7,640,000 | 0.69% |
| ARK Investment Management | 9,201,245 | $70,297,512 | 0.61% |